Matches in SemOpenAlex for { <https://semopenalex.org/work/W2987717899> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W2987717899 endingPage "vi138" @default.
- W2987717899 startingPage "vi138" @default.
- W2987717899 abstract "Abstract INTRODUCTION The new understanding of molecular pathways in cancer is paving the way towards personalized cancer medicine, especially in refractory disease. High-grade gliomas (HGG) are common pediatric brain tumors that tend to recur, with no available standard therapy upon recurrence. HGG are challenging tumors with illusive biology and poor outcome. We report here the molecular testing of 27 pediatric HGG patients. MATERIALS AND METHODS An analysis of pediatric patients with HGG treated at UT MD Anderson Cancer Center (MDACC) who underwent molecular genetic profiling using next generation sequencing with different genomic panels (AmpliSeq™Cancer Hotspot and Oncomine Panels – by Thermo Fisher Scientific). RESULTS 27 patients with HGG (median age 14 years, range 3–18 years old) underwent genomic profiling. Primary diagnoses were glioblastoma multiforme (n=22), anaplastic astrocytoma (n = 2), gliosarcoma (n= 1), anaplastic pleomorphic xanthoastrocytoma (n= 1) and anaplastic oligoastrocytoma (n= 1). There are 46 genes common to the panels used. The most common mutation was in TP53 (73%). Other mutations included PIK3CA (19%), IDH1 (11.5%), 7.7% for ATM, EGFR and PTEN, and 3.8% for BRAF, FGFR1 and FGFR2. 24 out of 27 patients were tested at initial diagnosis and 3 upon relapse/progression. Patients at initial diagnosis received standard of care therapy of radiation and temozolomide. Only 5 patients received targeted therapy upon progression/recurrence. Some challenges of genomically-matched therapy included lack of clinical trials accepting pediatric patients, unavailability of a liquid form of a drug, and insurance disapproval for off-label use. CONCLUSION The next generation of therapy for childhood cancers will be based upon in-depth molecular phenotyping that may facilitate the development of rational risk-adapted and target-based therapies. This cohort, though limited by sample size, highlights the opportunity to perform molecular testing and identification of alterations in actionable genes." @default.
- W2987717899 created "2019-11-22" @default.
- W2987717899 creator A5012403937 @default.
- W2987717899 creator A5013157173 @default.
- W2987717899 creator A5015150415 @default.
- W2987717899 creator A5022280464 @default.
- W2987717899 creator A5024356241 @default.
- W2987717899 creator A5024476694 @default.
- W2987717899 creator A5031795097 @default.
- W2987717899 creator A5043927389 @default.
- W2987717899 creator A5044421113 @default.
- W2987717899 creator A5060174624 @default.
- W2987717899 creator A5062789732 @default.
- W2987717899 creator A5062979200 @default.
- W2987717899 creator A5067055882 @default.
- W2987717899 creator A5076426660 @default.
- W2987717899 date "2019-11-01" @default.
- W2987717899 modified "2023-09-27" @default.
- W2987717899 title "INNV-40. TARGETED NEXT GENERATION SEQUENCING OF PEDIATRIC HIGH-GRADE GLIOMA AND ITS THERAPEUTIC IMPLICATIONS, MD ANDERSON EXPERIENCE" @default.
- W2987717899 doi "https://doi.org/10.1093/neuonc/noz175.579" @default.
- W2987717899 hasPublicationYear "2019" @default.
- W2987717899 type Work @default.
- W2987717899 sameAs 2987717899 @default.
- W2987717899 citedByCount "0" @default.
- W2987717899 crossrefType "journal-article" @default.
- W2987717899 hasAuthorship W2987717899A5012403937 @default.
- W2987717899 hasAuthorship W2987717899A5013157173 @default.
- W2987717899 hasAuthorship W2987717899A5015150415 @default.
- W2987717899 hasAuthorship W2987717899A5022280464 @default.
- W2987717899 hasAuthorship W2987717899A5024356241 @default.
- W2987717899 hasAuthorship W2987717899A5024476694 @default.
- W2987717899 hasAuthorship W2987717899A5031795097 @default.
- W2987717899 hasAuthorship W2987717899A5043927389 @default.
- W2987717899 hasAuthorship W2987717899A5044421113 @default.
- W2987717899 hasAuthorship W2987717899A5060174624 @default.
- W2987717899 hasAuthorship W2987717899A5062789732 @default.
- W2987717899 hasAuthorship W2987717899A5062979200 @default.
- W2987717899 hasAuthorship W2987717899A5067055882 @default.
- W2987717899 hasAuthorship W2987717899A5076426660 @default.
- W2987717899 hasBestOaLocation W29877178991 @default.
- W2987717899 hasConcept C121608353 @default.
- W2987717899 hasConcept C126322002 @default.
- W2987717899 hasConcept C143998085 @default.
- W2987717899 hasConcept C190283241 @default.
- W2987717899 hasConcept C2777389519 @default.
- W2987717899 hasConcept C2777609662 @default.
- W2987717899 hasConcept C2778227246 @default.
- W2987717899 hasConcept C2778880634 @default.
- W2987717899 hasConcept C2779083369 @default.
- W2987717899 hasConcept C2780265364 @default.
- W2987717899 hasConcept C2781230642 @default.
- W2987717899 hasConcept C32220436 @default.
- W2987717899 hasConcept C502942594 @default.
- W2987717899 hasConcept C509974204 @default.
- W2987717899 hasConcept C55493867 @default.
- W2987717899 hasConcept C60644358 @default.
- W2987717899 hasConcept C71924100 @default.
- W2987717899 hasConcept C86554907 @default.
- W2987717899 hasConcept C86803240 @default.
- W2987717899 hasConceptScore W2987717899C121608353 @default.
- W2987717899 hasConceptScore W2987717899C126322002 @default.
- W2987717899 hasConceptScore W2987717899C143998085 @default.
- W2987717899 hasConceptScore W2987717899C190283241 @default.
- W2987717899 hasConceptScore W2987717899C2777389519 @default.
- W2987717899 hasConceptScore W2987717899C2777609662 @default.
- W2987717899 hasConceptScore W2987717899C2778227246 @default.
- W2987717899 hasConceptScore W2987717899C2778880634 @default.
- W2987717899 hasConceptScore W2987717899C2779083369 @default.
- W2987717899 hasConceptScore W2987717899C2780265364 @default.
- W2987717899 hasConceptScore W2987717899C2781230642 @default.
- W2987717899 hasConceptScore W2987717899C32220436 @default.
- W2987717899 hasConceptScore W2987717899C502942594 @default.
- W2987717899 hasConceptScore W2987717899C509974204 @default.
- W2987717899 hasConceptScore W2987717899C55493867 @default.
- W2987717899 hasConceptScore W2987717899C60644358 @default.
- W2987717899 hasConceptScore W2987717899C71924100 @default.
- W2987717899 hasConceptScore W2987717899C86554907 @default.
- W2987717899 hasConceptScore W2987717899C86803240 @default.
- W2987717899 hasIssue "Supplement_6" @default.
- W2987717899 hasLocation W29877178991 @default.
- W2987717899 hasLocation W29877178992 @default.
- W2987717899 hasOpenAccess W2987717899 @default.
- W2987717899 hasPrimaryLocation W29877178991 @default.
- W2987717899 hasRelatedWork W1994455038 @default.
- W2987717899 hasRelatedWork W2039866113 @default.
- W2987717899 hasRelatedWork W2134519610 @default.
- W2987717899 hasRelatedWork W2808624194 @default.
- W2987717899 hasRelatedWork W2981284323 @default.
- W2987717899 hasRelatedWork W2987717899 @default.
- W2987717899 hasRelatedWork W3625525 @default.
- W2987717899 hasRelatedWork W4281668417 @default.
- W2987717899 hasRelatedWork W4295817416 @default.
- W2987717899 hasRelatedWork W59994307 @default.
- W2987717899 hasVolume "21" @default.
- W2987717899 isParatext "false" @default.
- W2987717899 isRetracted "false" @default.
- W2987717899 magId "2987717899" @default.
- W2987717899 workType "article" @default.